INCY
Incyte Corp.

5,543
Mkt Cap
$20.16B
Volume
1.97M
52W High
$109.28
52W Low
$53.56
PE Ratio
16.89
INCY Fundamentals
Price
$100.71
Prev Close
$102.69
Open
$101.94
50D MA
$98.12
Beta
0.51
Avg. Volume
2.35M
EPS (Annual)
$0.1549
P/B
4.25
Rev/Employee
$1.62M
Loading...
Loading...
News
all
press releases
Incyte (NASDAQ:INCY) Stock Price Down 3.4% - Time to Sell?
Incyte (NASDAQ:INCY) Trading Down 3.4% - Time to Sell...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·12h ago
News Placeholder
Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult...
Business Wire·19h ago
News Placeholder
Incyte Japan Announces Approval of Zynyz (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based...
Business Wire·19h ago
News Placeholder
Incyte (NASDAQ:INCY) EVP Sells $420,454.98 in Stock
Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Michael James Morrissey sold 4,323 shares of the business's stock in a transaction on Wednesday, December 17th. The shares were sold at an...
MarketBeat·4d ago
News Placeholder
Michael James Morrissey Sells 4,323 Shares of Incyte (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Michael James Morrissey sold 4,323 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of...
MarketBeat·4d ago
News Placeholder
Michael James Morrissey Sells 54,008 Shares of Incyte (NASDAQ:INCY) Stock
Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Michael James Morrissey sold 54,008 shares of the company's stock in a transaction dated Tuesday, December 16th. The shares were sold at an...
MarketBeat·4d ago
News Placeholder
EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi
INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.
Zacks·4d ago
News Placeholder
Incyte Announces European Commission Approval of Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with...
Business Wire·5d ago
News Placeholder
Incyte Corporation $INCY Stock Position Decreased by Ashford Capital Management Inc.
Ashford Capital Management Inc. decreased its position in Incyte Corporation (NASDAQ:INCY - Free Report) by 20.7% in the 2nd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·9d ago
<
1
2
...
>

Latest INCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.